218 related articles for article (PubMed ID: 11897583)
1. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication.
Kati WM; Montgomery D; Carrick R; Gubareva L; Maring C; McDaniel K; Steffy K; Molla A; Hayden F; Kempf D; Kohlbrenner W
Antimicrob Agents Chemother; 2002 Apr; 46(4):1014-21. PubMed ID: 11897583
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
3. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
[TBL] [Abstract][Full Text] [Related]
4. GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains.
Kati WM; Saldivar AS; Mohamadi F; Sham HL; Laver WG; Kohlbrenner WE
Biochem Biophys Res Commun; 1998 Mar; 244(2):408-13. PubMed ID: 9514938
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
McSharry JJ; McDonough AC; Olson BA; Drusano GL
Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Boivin G; Goyette N
Antiviral Res; 2002 Jun; 54(3):143-7. PubMed ID: 12062387
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
8. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities.
Smee DF; Huffman JH; Morrison AC; Barnard DL; Sidwell RW
Antimicrob Agents Chemother; 2001 Mar; 45(3):743-8. PubMed ID: 11181354
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
10. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.
Tai CY; Escarpe PA; Sidwell RW; Williams MA; Lew W; Wu H; Kim CU; Mendel DB
Antimicrob Agents Chemother; 1998 Dec; 42(12):3234-41. PubMed ID: 9835519
[TBL] [Abstract][Full Text] [Related]
11. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU
Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843
[TBL] [Abstract][Full Text] [Related]
13. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
Wu Y; Gao F; Qi J; Bi Y; Fu L; Mohan S; Chen Y; Li X; Pinto BM; Vavricka CJ; Tien P; Gao GF
J Virol; 2016 Dec; 90(23):10693-10700. PubMed ID: 27654293
[TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
15. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.
Leneva IA; Roberts N; Govorkova EA; Goloubeva OG; Webster RG
Antiviral Res; 2000 Nov; 48(2):101-15. PubMed ID: 11114412
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.
Mendel DB; Tai CY; Escarpe PA; Li W; Sidwell RW; Huffman JH; Sweet C; Jakeman KJ; Merson J; Lacy SA; Lew W; Williams MA; Zhang L; Chen MS; Bischofberger N; Kim CU
Antimicrob Agents Chemother; 1998 Mar; 42(3):640-6. PubMed ID: 9517945
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
18. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.
Govorkova EA; Fang HB; Tan M; Webster RG
Antimicrob Agents Chemother; 2004 Dec; 48(12):4855-63. PubMed ID: 15561867
[TBL] [Abstract][Full Text] [Related]
19. Influenza virus susceptibility and resistance to oseltamivir.
Aoki FY; Boivin G; Roberts N
Antivir Ther; 2007; 12(4 Pt B):603-16. PubMed ID: 17944268
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Mungall BA; Xu X; Klimov A
Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]